The most recent stock trade was executed by Chaitan Phd Khosla on 11 August 2020, trading 2,499 units of PTGX stock currently worth $4,723. Over the last 4 years, insiders at Protagonist Therapeutics have traded over $4,401,942 worth of Protagonist Therapeutics stock and bought 3,007,840 units worth $35,519,073 Mr. Gupta owns over 30,000 units of Protagonist Therapeutics stock worth over $1,100,880 and over the last 2 years he sold PTGX stock worth over $0. What is the salary of Mr Gupta? On average, Suneel trades about 7,500 units every 0 days since 2019. Mr. Gupta owns over 30,000 units of Protagonist Therapeutics stock worth over $938,025 and over the last 2 years he sold PTGX stock worth over $0. He received his Ph.D. in Pharmacokinetics from the University of Manchester, UK in 1987 and did a postdoctoral fellowship in Clinical Pharmacology at the University of California, San Francisco. As the Chief Development Officer of Protagonist Therapeutics, the total compensation of Suneel Gupta at Protagonist Therapeutics is $1,331,740. Prior to Impax, Dr. Gupta was Senior Vice President and Distinguished Research Fellow at Johnson & Johnson, where he led the early development from 2002 through 2008. Though, he is 1.73 m tall, he weighs about 65 kg. The oldest executive at Protagonist Therapeutics, Inc. is Lewis Williams, 70, who is the Independent Director. Mr. Gupta owns over 30,000 units of Protagonist Therapeutics stock worth over $917,730 and over the last few years he sold PTGX stock worth over $0. Suneel's mailing address filed with the SEC is 7707 Gateway Blvd #140, Newark, CA 94560, USA. In addition, he makes $1,331,740 as Chief Development Officer at Protagonist Therapeutics. Suneel Kumar Gupta is the Chairman & MD at Ashnoor Textile Mills. Most recently he bought 30,000 units of PTGX stock worth $153,900 on 3 December 2019. The oldest executive at Protagonist Therapeutics, Inc. is Lewis Williams, 70, who is the Independent Director. There are 1 executives at Protagonist Therapeutics getting paid more, with Dinesh Patel having the highest compensation of $1,948,340. The most active insiders traders include & Johnson Johnson & Johnson..., Capital Partners Gp, L.L.C...., and X L.P.Canaan Partners X Llc.... The largest trade he's ever made was buying 30,000 units of Protagonist Therapeutics stock on 3 December 2019 worth over $153,900. As the Chief Development Officer of Protagonist Therapeutics, the total compensation of Suneel Gupta at Protagonist Therapeutics is $1,331,740. Track performance, allocation, dividends, and risks, Annotate, download XLSX & look up similar tables, Filter, compare, and track coins & tokens. The estimated Net Worth of Suneel Gupta is at least $2.31 Milhão dollars as of 3 December 2019. Prior to joining Protagonist, he was Chief Scientific Officer of Impax Pharmaceuticals from 2008 to January 2019. As of 3 December 2019 he still owns at least 49,500 units of Protagonist Therapeutics stock. The largest trade he's ever made was buying 30,000 units of Protagonist Therapeutics stock on 3 December 2019 worth over $153,900. The estimated Net Worth of Suneel Gupta is at least $2.25 Million dollars as of 3 December 2019. You can see the complete history of Mr. Gupta stock trades at the bottom of the page. Suneel's mailing address filed with the SEC is 7707 Gateway Blvd #140, Newark, CA 94560, USA. The estimated Net Worth of Suneel Gupta is at least $2.35 Milión dollars as of 3 December 2019. As the Chief Development Officer of Protagonist Therapeutics, the total compensation of Suneel Gupta at Protagonist Therapeutics is $1,331,740. The estimated Net Worth of Suneel Gupta is at least $2.27 Million dollars as of 3 December 2019. Prior to Impax, Dr. Gupta was Senior Vice President and Distinguished Research Fellow at Johnson & Johnson, where he led the early development from 2002 through 2008. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA. On average, Suneel trades about 7,500 units every 0 days since 2019. The most recent stock trade was executed by Chaitan Phd Khosla on 11 August 2020, trading 2,499 units of PTGX stock currently worth $4,723. Mr. Gupta owns over 30,000 units of Protagonist Therapeutics stock worth over $1,138,500 and over the last 2 years he sold PTGX stock worth over $0. According to various media sources, his current net worth in the market is under review. Prior to joining Protagonist, he was Chief Scientific Officer of Impax Pharmaceuticals from 2008 to January 2019. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA. He received his Ph.D. in Pharmacokinetics from the University of Manchester, UK in 1987 and did a postdoctoral fellowship in Clinical Pharmacology at the University of California, San Francisco. Dr. Gupta serves on the scientific advisory boards of several pharmaceutical companies. In addition, he makes $1,331,740 as Chief Development Officer at Protagonist Therapeutics. Protagonist Therapeutics, Inc. engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. Dr. Gupta serves on the scientific advisory boards of several pharmaceutical companies. Prior to Johnson & Johnson, he held positions at ALZA Corporation from 1989 through 2001, where he had increasing levels of responsibility until ultimately being promoted to Vice President of Clinical Pharmacology & Product Discovery. Suneel Gupta Ph.D. serves as Chief Development Officer of the Company. Prior to Impax, Dr. Gupta was Senior Vice President and Distinguished Research Fellow at Johnson & Johnson, where he led the early development from 2002 through 2008. The estimated Net Worth of Suneel Gupta is at least $2.14 Million dollars as of 3 December 2019. There are 1 executives at Protagonist Therapeutics getting paid more, with Dinesh Patel having the highest compensation of $1,948,340. He received his Ph.D. in Pharmacokinetics from the University of Manchester, UK in 1987 and did a postdoctoral fellowship in Clinical Pharmacology at the University of California, San Francisco. The largest trade he's ever made was buying 30,000 units of Protagonist Therapeutics stock on 3 December 2019 worth over $153,900. Suneel Gupta is 62, he's been the Chief Development Officer of Protagonist Therapeutics since 2019. As of 3 December 2019 he still owns at least 49,500 units of Protagonist Therapeutics stock. In addition, he makes $1,331,740 as Chief Development Officer at Protagonist Therapeutics. The estimated Net Worth of Suneel Gupta is at least $2.25 Million dollars as of 3 December 2019. In addition, he makes $1,331,740 as Chief Development Officer at Protagonist Therapeutics. Over the last 4 years, insiders at Protagonist Therapeutics have traded over $4,401,942 worth of Protagonist Therapeutics stock and bought 3,007,840 units worth $35,519,073 Suneel's mailing address filed with the SEC is 7707 Gateway Blvd #140, Newark, CA 94560, USA. Last updated: 28 February 2020 at 5:49pm EST. In addition, he makes $1,331,740 as Chief Development Officer at Protagonist Therapeutics. The largest trade he's ever made was buying 30,000 units of Protagonist Therapeutics stock on 3 December 2019 worth over $153,900. As the Chief Development Officer of Protagonist Therapeutics, the total compensation of Suneel Gupta at Protagonist Therapeutics is $1,331,740. There are 1 executives at Protagonist Therapeutics getting paid more, with Dinesh Patel having the highest compensation of $1,948,340. Last updated: 28 February 2020 at 5:49pm EST. Suneel Gupta Ph.D. serves as Chief Development Officer of the Company. Suneel Gupta is 62, he's been the Chief Development Officer of Protagonist Therapeutics since 2019. There are 1 executives at Protagonist Therapeutics getting paid more, with Dinesh Patel having the highest compensation of $1,948,340. On average, Suneel trades about 7,500 units every 0 days since 2019. There are 7 older and 3 younger executives at Protagonist Therapeutics. Protagonist Therapeutics, Inc. engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. In addition, he makes $1,331,740 as Chief Development Officer at Protagonist Therapeutics. Dr. Gupta serves on the scientific advisory boards of several pharmaceutical companies. Most recently he bought 30,000 units of PTGX stock worth $153,900 on 3 December 2019. On average, Protagonist Therapeutics executives and independent directors trade stock every 28 days with the average trade being worth of $1,570,106. Prior to Impax, Dr. Gupta was Senior Vice President and Distinguished Research Fellow at Johnson & Johnson, where he led the early development from 2002 through 2008. There are 1 executives at Protagonist Therapeutics getting paid more, with Dinesh Patel having the highest compensation of $1,948,340. Mr. Gupta owns over 30,000 units of Protagonist Therapeutics stock worth over $1,138,500 and over the last 2 years he sold PTGX stock worth over $0. Mr. Gupta owns over 30,000 units of Protagonist Therapeutics stock worth over $1,015,740 and over the last 2 years he sold PTGX stock worth over $0. As of 3 December 2019 he still owns at least 49,500 units of Protagonist Therapeutics stock. The estimated Net Worth of Suneel Gupta is at least $2.1 Million dollars as of 3 December 2019. Suneel has made over 1 trades of the Protagonist Therapeutics stock since 2019, according to the Form 4 filled with the SEC. In addition, he makes $1,331,740 as Chief Development Officer at Protagonist Therapeutics. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA. The estimated Net Worth of Suneel Gupta is at least $2.47 Million dollars as of 3 December 2019. He received his Ph.D. in Pharmacokinetics from the University of Manchester, UK in 1987 and did a postdoctoral fellowship in Clinical Pharmacology at the University of California, San Francisco. . The most active insiders traders include & Johnson Johnson & Johnson..., Capital Partners Gp, L.L.C...., and X L.P.Canaan Partners X Llc.... The estimated Net Worth of Suneel Gupta is at least $2.13 million dollars as of 3 December 2019. In addition, he makes $1,331,740 as Chief Development Officer at Protagonist Therapeutics. Suneel Gupta is 62, he's been the Chief Development Officer of Protagonist Therapeutics since 2019. Mr. Gupta owns over 30,000 units of Protagonist Therapeutics stock worth over $1,038,510 and over the last 2 years he sold PTGX stock worth over $0. Protagonist Therapeutics executives and other stock owners filed with the SEC include: Track performance, allocation, dividends, and risks, Annotate, download XLSX & look up similar tables, Filter, compare, and track coins & tokens, Stocks and cryptocurrency portfolio tracker. In addition, he makes $1,331,740 as Chief Development Officer at Protagonist Therapeutics. On average, Protagonist Therapeutics executives and independent directors trade stock every 28 days with the average trade being worth of $1,588,058.

Wendee Lee Kickvic, Tony Mcdade Video, St Lucy Miracles, How Does The Wnba Survive, Remove Front Seat Hyundai Elantra, Stone Mountain Fall Colors, El Paso Cad, Pink Torch Coral, Aau Basketball Teams In Pittsburgh Pa,